MENU

Alexander Kutikov, MD, FACS

Clinical Locations

Primary Location

Fox Chase Cancer Center
333 Cottman Avenue
Philadelphia, PA 19111

Secondary Location

Fox Chase Cancer Center Huntingdon Pike
8 Huntingdon Pike
Rockledge, PA 19046

About

Chief, Division of Urology and Urologic Oncology

Professor, Department of Surgical Oncology

Roberta R. Scheller Chair in Urologic Oncology

American Urological Association's Urology Care Foundation, Prostate Health Committee Panel Member

Treatment Focus

Minimally Invasive Surgery, Robotic Surgery, Laparoscopic Surgery, Traditional Open Surgery
Prostate Cancer: robotic and open radical nerve-sparing prostatectomy
Bladder Cancer: urinary diversion, orthotopic neobladder reconstruction
Kidney Cancer: kidney-sparing approaches, robotic, laparoscopic, open kidney surgery.
Adrenal masses: minimally-invasive adrenal surgery and extensive expertise in treatment of adrenal incidentalomas.

Research Program

Key Awards

Language(s) Other than English

Russian

Treatment Philosophy

I am a surgical specialist who treats tumors of the adrenal, kidney, prostate, bladder, testis, and other genitourinary organs. Working closely with other members of the Fox Chase multidisciplinary team, I make certain that my patients are aware of all the choices that today's cutting edge oncological care has to offer, regardless of whether these treatments take place inside or outside the operating room.

When surgery is necessary, I strive to offer the best operation that fits an individual's particular condition and circumstance. Indeed, my unique fellowship training in both traditional open surgery and minimally-invasive approaches such as laparoscopy and robotics, allows me to offer a wide range of options that optimize oncological outcomes and minimize recovery time. For example, I am skilled at both open and robot-assisted nerve-sparing prostatectomy and open, laparoscopic, and robotic kidney surgery. Particularly, I have advanced expertise in kidney preservation. For patients with bladder cancer, I am able to offer both bladder-sparing approaches and the latest techniques in continent urinary reconstruction. Furthermore, I have a particular interest and expertise in treatment of various tumors and conditions that stem from the adrenal gland.

As a clinician at an academic institution such as Fox Chase, I actively participate in medical research. In particular, my academic interests focus on kidney, prostate, bladder, and adrenal disease. Being an active contributor to the medical literature, I hope to offer my patients the most up-to-date information on medical progress and, if necessary, help them enroll into appropriate clinical trials — many of which are only available through Fox Chase.

Modern oncology offers patients tremendous hope; however, today's treatment options can be overwhelming, especially to those who are trying to cope with the shock of a recent cancer diagnosis. I greatly appreciate the toll that such a diagnosis can take not only on the patient, but also on his or her family. I hope to bring to every one of my patients a sense of understanding and compassion that can help us effectively work together to achieve the best outcome that modern medicine has to offer.

 
Education and Training

Educational Background

  • Fellow, Society of Urologic Oncology, Fox Chase Cancer Center, Philadelphia, PA
  • Chief Resident, Urology, University of Pennsylvania, Philadelphia, PA, 2007-2008
  • Resident, Urology, University of Pennsylvania, Philadelphia, PA, 2004-2007
  • MD, Harvard Medical School, Harvard-MIT Health Sciences and Technology Program, Boston, MA, 2003

Certifications

  • American Board of Urology, Board Certified

Memberships

  • Society of Urologic Oncology
  • American Urological Association
  • American College of Surgeons
  • Philadelphia Urological Society

Honors & Awards

  • Young Urologist of the Year, Mid-Atlantic Section, American Urological Association, 2021
  • Philadelphia Magazine Top Doctors, 2017-21
  • Best Doctors in America® , 2019-2020, Urology
  • Everyday Hero Award, Pennsylvania Medical Society (PAMED), 2018
  • America's Top Doctors®2016-17
  • BJU International Journal Best Mobile App Award for drawMD Urology iPad Application, American Urological Association Meeting, San Diego, CA, 2013
  • Mid-Atlantic AUA Young Investigator Representative to the AUA’s Research Forum, American Urological Association Meeting, Washington, DC, 2011
  • CaPSURE Scholar, CaPSURE Scholars Program in Prostate Cancer Outcomes Research, 2009-10
  • American College of Surgeons Excellence in Research Award 96th Annual Clinical Congress, Surgical Forum, 2010
Patient Stories

William Bojanowski

Neuroendocrine Tumors

William Bojanowski

Neuroendocrine Tumors

In October of 2020, at 59 years old, I started having some back pain. I worked in construction, so lower back pain was normal, but this time the pain was in my upper back. I went to my primary doctor and she noticed that my kidney was not functioning fully. She thought it might be due to my diabetes medication.

After two months of a lowered dosage of medication, my pain only got worse. I was sent to the local urologist, and when he saw something on my X-rays he immediately referred me to Fox Chase Cancer Center.

Donna McAllister

Bladder Cancer

Donna McAllister

Bladder Cancer

I was treated with compassion, given hope, and kept informed of every facet of my treatment.

Edward Enoch

Prostate Cancer

Edward Enoch

Prostate Cancer

My name is Edward Enoch, and I am from Lansdale, Pennsylvania. I was sixty years old and two years retired when my life took a startling turn.

Like millions of other retirees, my wife Janice and I were updating our health insurance. We met with an agent who asked that I schedule a routine checkup. I thought nothing of it at the time—after all, I had no complaints about my health. However, once I received the results of my blood test, the confidence I had regarding my health started to waver.

Charles "Cha" Goods

Prostate Cancer

Charles "Cha" Goods

Prostate Cancer

I’ve been a tennis coach for nearly 17 years, the last dozen at Legacy Youth Tennis and Education in Philadelphia. I run group clinics and offer private lessons. I specialize in movement and footwork training, as well as video-based training. My students range from kids as young as five to professional tennis players. I’m an active coach. When I teach my students how to do something, I want to show them I can do it. They’re amazed at how good I am!

Annie Dunn

Kidney Cancer

Annie Dunn

Kidney Cancer

I have always enjoyed being social and keeping busy with a handful of hobbies. At 68, I spent most of my time cycling with my husband Tom, going on walks, reading whatever I could find, and socializing with friends. Up until recently, those things had always been a regular part of my life. However, after being diagnosed with kidney cancer amid the COVID-19 pandemic, those activities had to take a back seat.

Pages

Research Profile

Research Program

Research Interests

Dr. Kutikov has authored over 140 peer-reviewed publications.  His current research interests include understanding carcinogenesis of genitourinary cancers, risk-stratification of surgical outcomes, and quantification of competing risks.  He serves on editorial boards of academic journals, including being the Associate Editor of Digital Media for European Urology, the field of Urology's leading academic publication.

Dr. Kutikov also has significant interests in harnessing web and mobile technology to improve patient engagement and quality of care.  He is a co-founder of several ventures that strive to improve physician education and patient care.  

Lab Overview

In collaboration with Vladimir Kolenko, MD, PhD, and Robert Uzzo, MD, our research efforts span the basic and the clinical sciences. Our work focuses on understanding the process of renal and prostatic carcinogenesis and assessing novel therapeutic regimens for the treatment of urological cancers.

As part of our work, we explore the role of zinc in development and progression of prostate malignancy.  Zinc concentrations diminish early in the course of prostate carcinogenesis—prior to histopathological changes—and continue to decline during progression toward castration-resistant growth. The objective of research in our laboratory is to test and advance an emerging paradigm that intracellular zinc deficiency augments malignant potential of prostate cancer cells and, therefore, promotes prostate tumorigenesis. We are also investigating the role of zinc chelators as potential therapeutic agents for the treatment of castration-resistant prostate cancer. Work performed by Dr. Kolenko indicates that treatment of prostate cancer cells with the zinc chelating agent TPEN induces selective down-regulation of X-linked inhibitor of apoptosis protein (XIAP) and sensitizes cancer cells to cytotoxic agents. Importantly, the observed effect is not limited to prostate cancer, as TPEN reduces expression of XIAP in malignant cell lines of various origins, e.g. colon, ovarian, leukemia, breast and cervical.

The second major theme of our research is to determine the mechanism of tyrosine kinase inhibitor (TKIs)-resistance in genitourinary tumors. Our studies reveal that TKI-resistance coincides with the loss of phosphatase and tensin homolog (PTEN) protein expression in prostate and renal malignant cells. On the contrary, expression of PTEN sensitizes prostate and renal tumors to multi-targeted tyrosine kinase inhibitor sunitinib both in vitro and in vivo. In addition, our studies indicate that an increase in expression of IL-6 and IL-8 correlates with sunitinib and pazopanib resistance in prostate and renal tumor cells. Use of a reliable biomarker for TKI response, harbors promise both in the clinical and research settings.

In the clinical arena, we focus our efforts on addressing quantification of competing risks of death for patients with urologic malignancies, investigating the biology and natural history of small renal masses, improving reporting and risk-stratification of surgical outcomes for patients with kidney cancer, and addressing clinical approaches to patients with adrenal cancers and incidental adrenal masses.

Publications

Selected Publications

A. G. McIntosh, D. C. Parker, B. L. Egleston, R. G. Uzzo, H. Haseebuddin, S. S. Joshi, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, M. C. Smaldone, and Kutikov, “Prediction of Significant Estimated Glomerular Filtration Rate Decline Following Renal Unit Removal to Aid in the Clinical Choice between Radical and Partial Nephrectomy in Patients with Renal Mass and Normal Renal Function,” BJU Int, May 2019. PubMed

H. Borgmann, M. Cooperberg, D. Murphy, S. Loeb, J. N’Dow, M. J. Ribal, H. Woo, M. Rouprêt, A. Winterbottom, C. Wijburg, M. Wirth, J. Catto, and A. Kutikov, “Online Professionalism—2018 Update of European Association of Urology (@Uroweb) Recommendations on the Appropriate Use of Social Media,” European Urology, pp. 1–7, Aug. 2018. PubMed

M. C. Smaldone, B. Egleston, J. M. Hollingsworth, B. K. Hollenbeck, D. C. Miller, T. M. Morgan, S. P. Kim, A. Malhotra, E. Handorf, Y.-N. Wong, R. G. Uzzo, and A. Kutikov, “Understanding Treatment Disconnect and Mortality Trends in Renal Cell Carcinoma Using Tumor Registry Data,” Med Care, vol. 55, no. 4, pp. 398–404, Apr. 2017. PubMed

N. Waingankar, K. Mallin, M. Smaldone, B. L. Egleston, A. Higgins, D. P. Winchester, R. G. Uzzo, and A. Kutikov, “Assessing the relative influence of hospital and surgeon volume on short-term mortality after radical cystectomy,” BJU Int, vol. 120, no. 2, pp. 239–245, Aug. 2017. PubMed

B. T. Ristau, D. Y. T. Chen, J. Ellis, A. Malhotra, L. DeMora, R. B. Parsons, B. Milestone, M. Brody, R. Viterbo, R. Greenberg, M. Smaldone, R. Uzzo, J. Anaokar, and A. Kutikov, “Defining Novel and Practical Metrics to Assess the Deliverables of Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Prostate Biopsy,” The Journal of Urology, Oct. 2017. PubMed

S. P. Kim, S. C. Campbell, I. Gill, B. R. Lane, H. Van Poppel, M. C. Smaldone, A. Volpe, and A. Kutikov, “Collaborative Review of Risk Benefit Trade-offs Between Partial and Radical Nephrectomy in the Management of Anatomically Complex Renal Masses,” European Urology, vol. 72, no. 1, pp. 64–75, Jul. 2017. PubMed

A. Kutikov, H. H. Woo, and J. W. Catto, “Urology Tag Ontology Project: Standardizing Social Media Communication Descriptors,” European Urology, vol. 69, no. 2, pp. 183–185, Feb. 2016. PubMed

A. Kutikov, M. C. Smaldone, R. G. Uzzo, M. Haifler, G. Bratslavsky, and B. C. Leibovich, “Renal Mass Biopsy: Always, Sometimes, or Never?,” European Urology, vol. 70, no. 3, pp. 403–406, Sep. 2016. PubMed

E. R. Plimack, R. L. Dunbrack, T. A. Brennan, M. D. Andrake, Y. Zhou, I. G. Serebriiskii, M. Slifker, K. Alpaugh, E. Dulaimi, N. Palma, J. Hoffman-Censits, M. Bilusic, Y.-N. Wong, A. Kutikov, R. Viterbo, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, E. J. Trabulsi, R. Yelensky, D. J. McConkey, V. A. Miller, E. A. Golemis, and E. A. Ross, “Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer,” European Urology, vol. 68, no. 6, pp. 959–967, Dec. 2015. PubMed

S. Ginzburg, R. Uzzo, J. Walton, C. Miller, D. Kurz, T. Li, E. Handorf, R. Gor, A. Corcoran, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, M. C. Smaldone, and A. Kutikov, “Residual Parenchymal Volume, Not Warm Ischemia Time, Predicts Ultimate Renal Functional Outcomes in Patients Undergoing Partial Nephrectomy.,” Urology, vol. 86, no. 2, pp. 300–306, Aug. 2015.   PubMed

B. Shuch, A. Amin, A. J. Armstrong, J. N. Eble, V. Ficarra, A. Lopez-Beltran, G. Martignoni, B. I. Rini, and A. Kutikov, “Understanding Pathologic Variants of Renal Cell Carcinoma: Distilling Therapeutic Opportunities from Biologic Complexity,” European Urology, vol. 67, no. 1, pp. 85–97, Jan. 2015. PubMed

E. R. Plimack, J. H. Hoffman-Censits, R. Viterbo, E. J. Trabulsi, E. A. Ross, R. E. Greenberg, D. Y. T. Chen, C. D. Lallas, Y.-N. Wong, J. Lin, A. Kutikov, E. Dotan, T. A. Brennan, N. Palma, E. Dulaimi, R. Mehrazin, S. A. Boorjian, W. K. Kelly, R. G. Uzzo, and G. R. Hudes, “Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity,” J. Clin. Oncol., vol. 32, no. 18, pp. 1895–1901, Jun. 2014. PubMed

A. Minervini, M. Carini, R. G. Uzzo, R. Campi, M. C. Smaldone, and A. Kutikov, “Standardized Reporting of Resection Technique During Nephron-sparing Surgery: The Surface-Intermediate-Base Margin Score.,” European Urology, Jun. 2014.    PubMed

A. Kutikov, P. Makhov, K. Golovine, D. J. Canter, M. Sirohi, R. Street, J. Simhan, R. G. Uzzo, and V. M. Kolenko, “Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer,” Urology, vol. 78, no. 4, pp. 968.e7–11, Oct. 2011. PubMed

A. Kutikov, M. C. Smaldone, B. L. Egleston, B. J. Manley, D. J. Canter, J. Simhan, S. A. Boorjian, R. Viterbo, D. Y. T. Chen, R. E. Greenberg, and R. G. Uzzo, “Anatomic Features of Enhancing Renal Masses Predict Malignant and High-Grade Pathology: A Preoperative Nomogram Using the RENAL Nephrometry Score,” European Urology, vol. 60, no. 2, pp. 241–248, Aug. 2011.   PubMed

A. Kutikov, B. L. Egleston, Y.-N. Wong, and R. G. Uzzo, “Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram,” J. Clin. Oncol., vol. 28, no. 2, pp. 311–317, Jan. 2010. PubMed

A. Kutikov and R. G. Uzzo, “The R.E.N.A.L. nephrometry score: a comprehensive standardized system for quantitating renal tumor size, location and depth,” The Journal of Urology, vol. 182, no. 3, pp. 844–853, Sep. 2009. PubMed

Additional Publications

Full List of Publications

Ratings

374 PATIENT SATISFACTION REVIEWS

Our Patient Satisfaction Rating is an average of all responses to care provider related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Learn more.

OVERALL RATING

4.9 / 5.0

RATINGS BREAKDOWN

  • 4.9
  • 4.9
  • 4.9
  • 4.9
  • 4.8

114 PATIENT COMMENTS

  • 5.0
    October 24, 2021
    I really like my team, from front desk to the Dr. I love em all
  • No Star Ratings Available October 16, 2021
    I have been extremely treated excellent with my physicians ( kutikov & [...] ). I have great experience and will never forget about their service
  • No Star Ratings Available October 15, 2021
    Dr. Kutikov provides outstanding care has a great way to deliver good messages under difficult circumstances
  • No Star Ratings Available October 15, 2021
    I have and would recommend Dr. Kutikov and Pa. [...] to several people. They saved my life and they are THE BEST! I will keep recommending the whole Fox Chase team to others as need occurs. Everyone that treated me was top notch and so courteous. I never felt like I was out of the loop.
  • No Star Ratings Available October 15, 2021
    Dr. Kutikov was proactive in my care and made sure I understood everything he was explaining and [...] has done an amazing job with the follow up appointments. She is making sure that my other doctors are aware of where we stand so that they may make decisions based the assessments of my test.
  • 5.0
    October 08, 2021
    I have great confidence in Dr. Kutikov.
  • 5.0
    October 02, 2021
    Good experience, first time to this doctor & the facility
  • 5.0
    September 28, 2021
    All personnel were extreemly professional
  • 5.0
    September 27, 2021
    Dr. Kutikov and his staff at the office are the most professional and caring medical people I have ever been to. EXCELLENT JOB!!! All the way around!
  • 5.0
    September 20, 2021
    I feel that I am getting the best possible care available for someone whom has cancer. The follow up is excellent and so is the surgeon.
  • 5.0
    September 10, 2021
    Dr. Kutikov treated me with great respect and concern, it was the first time I've met him, but he put me at ease, and was very attentive to my concerns.
  • 5.0
    September 10, 2021
    We love Dr Kutikov! He is awesome!He has a wonderful bedside manner and made us feel relaxed and confident that everything will be alright! He is so knowledgeable and we feel that he had our best interest in mind. His nurses are awesome too!
  • No Star Ratings Available September 10, 2021
    Dr. Kutikov is the best
  • 5.0
    August 29, 2021
    All good
  • 5.0
    August 29, 2021
    Dr. Kutikov and his staff are the best. I have been seeing them for 7 years for my cancer and have always had a good experience dealing with them. I recommend that Dr. To my friends if needed.
  • 5.0
    August 15, 2021
    Good
  • 5.0
    August 13, 2021
    I told my provider I would love not to be on dialysis he said he would do his best and he did. I am ecstatic.
  • 5.0
    August 13, 2021
    Dr. Kutikov is a wonderful doctor, people have a lot of good things to say about him.
  • 5.0
    July 30, 2021
    Dr Kutikov and his staff has been a wonderful experience for a patient. I have recommended others who have similar issues to make an appointment with his team.
  • 5.0
    July 28, 2021
    Dr. Kutikov and his staff are wonderful, caring people!
LOAD MORE

Connect with Fox Chase